Patient-controlled analgesic infusions: alfentanil versus morphine

Area of Science:

• Oncology
• Pharmacology
• Pain Management

Background:

• Patient-controlled intravenous infusion systems (PCA) improve pain management in cancer patients.
• Pharmacokinetically-based PCA (PKPCA) optimizes drug delivery for enhanced pain relief.
• Oral mucositis is a common and painful side effect in bone marrow transplant (BMT) patients.

Purpose of the Study:

• To compare the efficacy and side-effect profiles of alfentanil and morphine in BMT patients with oral mucositis pain.
• To evaluate the use of a PKPCA system for self-administration of opioid analgesics.
• To investigate potential differences in analgesic tolerance between alfentanil and morphine.

Main Methods:

• A PKPCA system was used for self-administration of either alfentanil or morphine.
• Efficacy was measured by pain relief and side-effect intensity.
• Plasma concentrations of the analgesics were monitored.

Main Results:

• Patients receiving morphine via PKPCA reported greater pain relief than those receiving alfentanil during the initial 4 days of therapy.
• No significant differences in side-effect intensities were observed between the alfentanil and morphine groups.
• Higher plasma concentrations of alfentanil were required to achieve pain relief comparable to morphine, suggesting potential tolerance development.

Conclusions:

• Morphine demonstrated superior short-term efficacy over alfentanil for managing oral mucositis pain in BMT patients using PKPCA.
• The development of analgesic tolerance to alfentanil may be more rapid than to morphine.
• Alfentanil's utility in long-term pain management for BMT patients could be limited by its potential for rapid tolerance onset.